Donaldson Company, Inc. — Fiscal 2024 Q3 Form 10-Q
Reporting period: Quarter and nine months ended April 30, 2024. Donaldson is a global filtration-products company with Mobile Solutions, Industrial Solutions and Life Sciences segments. Amounts below are in millions, except per-share data and ratios.
Financial performance
| Metric | Q3 FY2024 | Q3 FY2023 | Nine months FY2024 | Nine months FY2023 |
|---|---|---|---|---|
| Net sales | $927.9 | $875.7 | $2,650.9 | $2,551.3 |
| Gross profit / margin | $330.1 / 35.6% | $288.8 / 33.0% | $939.6 / 35.4% | $860.5 / 33.7% |
| Operating income / margin | $143.6 / 15.5% | $124.0 / 14.2% | $397.9 / 15.0% | $359.6 / 14.1% |
| Net earnings | $113.5 | $93.7 | $304.3 | $266.9 |
| Diluted EPS | $0.92 | $0.76 | $2.48 | $2.16 |
| Operating cash flow | Not separately stated | Not separately stated | $366.5 | $353.7 |
Q3 sales rose 6.0% and net earnings increased 21.1%; nine-month sales rose 3.9% and net earnings increased 14.0%. Gross margin improvement reflected higher volume, pricing and, in Q3, input-cost deflation. SG&A and R&D increased, including from headcount and investment in acquired Life Sciences businesses. Nine-month interest expense rose to $16.1 from $14.3, primarily due to higher variable rates.
Segments and material changes
- Mobile Solutions: Q3 sales increased 5.5% to $585.2 and pretax earnings rose to $107.9 from $83.4. Aftermarket growth and margin improvement helped offset weaker Off-Road demand, particularly in agriculture.
- Industrial Solutions: Q3 sales increased 2.9% to $269.1; pretax earnings were $50.3 versus $49.1, with margin roughly flat. Nine-month sales increased 5.6%, supported by industrial filtration, power generation and aerospace/defense demand.
- Life Sciences: Q3 sales rose 24.2% to $73.6, but pretax earnings were only $0.5. For nine months, sales rose 8.4% to $196.7 while the segment recorded a $9.5 pretax loss, versus $17.3 pretax earnings a year earlier. The company attributed the decline to investments to scale acquired businesses; Q3 sales also benefited from timing of bioprocessing equipment sales and disk-drive demand.
For the nine-month period, sales growth reflected volume, pricing and market-share gains. Foreign currency translation reduced Q3 sales by $7.1 but increased nine-month sales by $10.1. The company reported no material restructuring charges in FY2024; prior-year results included organizational redesign and customer-program exit charges.
Cash, debt and liquidity
- Cash and equivalents were $223.7 at April 30, 2024, up from $187.1 at July 31, 2023. Current assets were $1,400.7 and current liabilities $735.2 (approximately 1.9x current ratio).
- Nine-month operating cash flow was $366.5. Capital expenditures were $65.8; cash used in investing was $67.8, compared with $155.1 a year earlier, mainly reflecting lower acquisition spending.
- Cash used in financing was $257.5, including $228.8 of long-term debt repayments, $113.8 of treasury-stock purchases and $90.3 of dividends, partly offset by debt proceeds and stock-option exercises.
- Short-term borrowings were $49.4; current maturities of long-term debt were $25.0; long-term debt was $481.8. Management reported total debt at 27.3% of capitalization, down from 33.2% at July 31, 2023, and compliance with debt covenants.
- The company reported $382.5 available on its $500.0 revolving credit facility, which expires May 21, 2026, and $573.4 capacity under existing credit facilities overall. Management believes cash, operating cash generation and available credit will meet requirements for the next 12 months and beyond.
Outlook, risks and unusual items
The filing provides no quantified sales or earnings guidance. Management cites global economic and geopolitical conditions, demand fluctuations, raw-material availability and costs, competitive pricing, foreign exchange, interest rates, acquisitions, and execution and technology risks as factors that could affect results. The filing states that current operating results are not necessarily indicative of future periods.
Donaldson entered a definitive agreement to acquire a 49% stake in Medica S.p.A., subject to tender-offer acceptance, with an option to acquire the remaining 51% later. No material FY2024 acquisitions had been completed as of the filing. The company also disclosed a $3.1 pension-settlement charge in Q3. Recorded liabilities for claims and litigation were not material; management considers material excess over accruals remote. The company guarantees 50% of certain AFSI joint-venture debt; AFSI debt was $49.7 at quarter-end. Unrecognized tax benefits were $17.3, with $2.6 of accrued interest and penalties.
Other notable exposures include variable-rate debt and commodity costs. The company estimated that a 0.5 percentage-point rise in short-term rates would have increased nine-month interest expense by approximately $1.0. Foreign-currency forward contracts and cross-currency swaps are used for hedging, not speculation.
Important facts for investors to verify
- Whether Life Sciences investment spending translates into improved segment profitability, given its nine-month pretax loss despite sales growth.
- How much future growth comes from recurring aftermarket demand versus cyclical or timing-sensitive markets, including agriculture and bioprocessing equipment.
- Debt and credit-facility availability, including the reported facility capacity and upcoming May 2026 revolver expiry.
- Medica tender-offer completion, purchase terms and any subsequent decision on the remaining stake.
- Exposure to variable interest rates, foreign-exchange movements, commodity inflation and AFSI guarantees.
- The filing’s reported metrics and timing: results are unaudited, and the nine-month cash-flow period is not the same as the three-month earnings period.